139 related articles for article (PubMed ID: 25469850)
1. Emerging treatments for amyloidosis.
Sayed RH; Hawkins PN; Lachmann HJ
Kidney Int; 2015 Mar; 87(3):516-26. PubMed ID: 25469850
[TBL] [Abstract][Full Text] [Related]
2. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of amyloidosis.
Rajkumar SV; Gertz MA
N Engl J Med; 2007 Jun; 356(23):2413-5. PubMed ID: 17554124
[No Abstract] [Full Text] [Related]
4. [Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis].
Ikeda SI
Brain Nerve; 2013 Jul; 65(7):831-42. PubMed ID: 23832986
[TBL] [Abstract][Full Text] [Related]
5. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
6. [Can amyloidosis regress?].
Dray JM; Blétry O
Rev Prat; 1997 Oct; 47(16):1798-801. PubMed ID: 9453206
[TBL] [Abstract][Full Text] [Related]
7. Novel Treatments for Hereditary ATTRv Amyloidosis.
González-Duarte A
JAMA; 2023 Oct; 330(15):1433-1434. PubMed ID: 37768648
[No Abstract] [Full Text] [Related]
8. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatments of AL and ATTR amyloidosis.
Chandrashekar P; Desai AK; Trachtenberg BH
Heart Fail Rev; 2022 Sep; 27(5):1587-1603. PubMed ID: 34783948
[TBL] [Abstract][Full Text] [Related]
10. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
11. Penile ulcers complicating systemic AL amyloidosis: a case report.
Arun M; Sloan SB; Shelton A; Sanchorawala V
Amyloid; 2016 Sep; 23(3):203-204. PubMed ID: 27187183
[No Abstract] [Full Text] [Related]
12. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
13. Novel pharmacotherapies for cardiac amyloidosis.
Alexander KM; Singh A; Falk RH
Pharmacol Ther; 2017 Dec; 180():129-138. PubMed ID: 28648829
[TBL] [Abstract][Full Text] [Related]
14. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin amyloidosis and the kidney.
Lobato L; Rocha A
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1337-46. PubMed ID: 22537653
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of transthyretin aggregation and toxicity.
Gasperini RJ; Klaver DW; Hou X; Aguilar MI; Small DH
Subcell Biochem; 2012; 65():211-24. PubMed ID: 23225005
[TBL] [Abstract][Full Text] [Related]
18. Amyloid proteins, precursors, mediator, and enhancer.
Cohen AS; Shirahama T; Sipe JD; Skinner M
Lab Invest; 1983 Jan; 48(1):1-4. PubMed ID: 6401828
[No Abstract] [Full Text] [Related]
19. Amyloidosis: a clinico-pathophysiological synopsis.
Hirschfield GM
Semin Cell Dev Biol; 2004 Feb; 15(1):39-44. PubMed ID: 15036205
[TBL] [Abstract][Full Text] [Related]
20. Emerging Advances in the Management of Cardiac Amyloidosis.
Vranian MN; Sperry BW; Valent J; Hanna M
Curr Cardiol Rep; 2015 Nov; 17(11):100. PubMed ID: 26374453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
